Clinical Trial

Music Effect on the Self-Injection, Testing Fear and Pain

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 28, 2025 (before its estimated May 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Diabetes is a chronic and broad-spectrum metabolic disorder characterized by hyperglycemia that occurs due to relative or absolute insulin deficiency or "insulin resistance" developed against insulin action in peripheral tissues, affecting many organs and causing multisystem involvement. Metabolic function continues to deteriorate after diagnosis, leading to worsening glycemic control and insulin therapy becoming necessary. However, patients may have difficulty adhering to insulin therapy. Fears about injections are common in both adults and children and, as research shows, are a major reason why people with diabetes avoid taking insulin. Addressing these fears is an important part of helping patients reduce their risk of diabetes-related complications. Helping patients manage their replacement pain may help reduce the effects of needle fear in the future. There are a number of strategies that can ease the pain.The use of music in pain management has advantages such as being reliable, cheap, and having no side effects, as well as reducing postoperative pain reports. Music distracts the individual from negative stimuli and allows them to focus on something they enjoy, thus reducing pain and anxiety. Music therapy has also been shown to have sedative-protective effects and reduce stress hormone levels. Listening to preferred music can distract and reduce the pain and negative emotions associated with an unpleasant experience.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-18.
Trial Details
NCT Number NCT06790550
Lead Sponsor Dicle University
Conditions Type 2 Diabetes Mellitus (T2DM), Insulin, Fear, Pain, Injection, Music Therapy
Enrollment 100 participants
Start Date 2025-01-30
Primary Completion 2025-05-30 (estimated)
Study Completion 2025-07-30 (estimated)
Updated on ClinicalTrials.gov 2025-01-28